Abstract
Prostate cancer (PC) biomarker-citrate detection is clinically important to diagnose PC in early stages. Methylquinolinium iodide (Q) conjugated indole-phenylboronic acid (IB) was designed as a red-emissive QIB probe for the detection of citrate through Lewis acid–base reaction and intramolecular charge transfer (ICT) sensing mechanisms. Boronic acid acts as Lewis acid as well as citrate (Lewis base) recognition unit. The probe reacted with citrate, showing enhanced red emissions. Since the probe has excellent water solubility and great biocompatibility, practical application in biological systems is possible. Citrate was monitored precisely in the mitochondria organelle (in vitro) of living cells with a positive charge on QIB. Also, endogenous (in situ) citrate was detected quantitatively to discriminate non-cancerous and PC mice, observed strong and lower (negligible) emission intensity on non-cancerous and cancerous prostate tissues, respectively. Because, the concentration of citrate is higher in healthy prostate compared with PC prostate. Furthermore, the analysis of sliced prostate tissues can give PC-related information for clinical diagnosis to prevent and treat PC in the initial stages. Therefore, we believe that the present probe is a promising biochemical reagent in diagnosing PC.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
